ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Clinical types of checkpoint inhibitor-related pneumonitis in lung cancer patients: a multicenter experience

Lin, Xinqing; Deng, Haiyi; Chen, Likun; Wu, Di; Chen, Xiaobo; Yang, Yilin; Chen, Tao; Xie, Xiaohong; Xie, Zhanhong; Liu, Ming; Ouyang, Ming; Qin, Yinyin; Li, Shiyue; Zhong, Nanshan; Gregg, Jeffrey P.; Horita, Nobuyuki; Song, Yong*; Zhou, Chengzhi*广州医学院; 南方医科大学; 中山大学; 1; y
Translational Lung Cancer Research2021-1DOI: 10.21037/tlcr-20-1258
12被引11阅读
引用收藏
分享

摘要

Background: Checkpoint inhibitor-related pneumonitis (CIP) is not well classified according to clinical factors. We propose different clinical sub-types of CIP based on clinical factors and investigated the corresponding clinical features, treatments, and outcomes. @@@ Methods: We conducted a multicenter retrospective study of patients with lung cancer (including non-small cell lung cancer and small cell lung cancer) who developed CIP. The clinical characteristics, radiologic features, treatments, and outcomes of CIP were analyzed. @@@ Results: A total of 55 patients developed CIP and were classified into 3 groups as follows: 21 in the pure type (PT) group, 14 in the induced type (IT) group, and 20 in the mixed type (MT) group. The incidence of severe (grade 3-5) pneumonitis was significantly higher in the IT group than in the PT and MT groups (71.4% vs. 14.3% vs. 50.0%, P=0.002). Antiviral therapy was significantly more frequent in the IT group than in the PT and MT groups. Antibiotic therapy was administered in 23.8%, 71.4%, and 80.0% of patients with the PT, IT, and MT, respectively. The improvement time in the PT group was longer than that in the IT and MT groups (0.9 vs. 0.5 vs. 0.3 months, P=0.028). Patients with the PT had a better tumor response to immune checkpoint inhibitors (ICIs) than those with the other 2 types [overall response rate (ORR), 78% vs. 31% vs. 44%, P=0.027]. @@@ Conclusions: The clinical classification of CIP may favor strategies for treatments and predict the tumor response to ICIs.

学科与关键词

关键词
Immune checkpoint inhibitor (ICI)immune-related adverse eventscheckpoint inhibitor-related pneumonitis (CIP)lung cancerclinical types
相关
加载中…
  • Proposed clinical phases for the improvement of personalized treatment of checkpoint inhibitor-related pneumonitis
    Zhou, Chengzhi; Yang, Yilin; Lin, Xinqing; Fang, Nianxin; Chen, Likun; Jiang, Juhong; Deng, Haiyi; Deng, Yu; Wan, Minghui; Qiu, Guihuan; Sun, Ni; Wu, Di; Long, Xiang; Zhong, Changhao; Xie, Xiaohong; Xie, Zhanhong; Liu, Ming; Ouyang, Ming; Qin, Yinyin; Petrella, Francesco; Fiorelli, Alfonso; Bravaccini, Sara; Kataoka, Yuki; Watanabe, Satoshi; Goto, Taichiro; Solli, Piergiorgio; Igai, Hitoshi; Saito, Yuichi; Tsoukalas, Nikolaos; Nakada, Takeo; Li, Shiyue*; Chen, Rongchang*Frontiers in Immunology, 2022, 13: 935779.被引 6
  • Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis
    Lin, Xinqing; Deng, Jiaxi; Deng, Haiyi; Yang, Yilin; Sun, Ni; Zhou, Maolin; Qin, Yinyin; Xie, Xiaohong; Li, Shiyue; Zhong, Nanshan; Song, Yong*; Zhou, Chengzhi*Frontiers in Immunology, 2022, 12: 818492.被引 13
  • Risk Factors for Refractory Immune Checkpoint Inhibitor-related Pneumonitis in Patients With Lung Cancer
    Tan, Peixin; Huang, Wei; He, Xinyan; Lv, Fengquan; Cui, Yanhai*; Du, Shasha*Journal of Immunotherapy, 2023, 46(2): 64-73.被引 3
查看全部 →

发表信息

论文状态
公开发表
期刊
Translational Lung Cancer Research
发表日期
2021-01
卷期
第 10 卷, 第 1 期
页码
415-429
DOI
10.21037/tlcr-20-1258
期刊收录
NSL
期刊等级
2区
成果收录
SCIE
资助标注
Guangdong High-Level University Clinical Cultivation Project [2017-21020]; Guangzhou Science and Technology Program key projects [202008010006]; Wu Jieping Medical Foundation [20201101]

作者

  • L

    Lin, Xinqing (第一作者)

    1 · southern med univ · guangzhou med univ

  • D

    Deng, Haiyi

    1 · guangzhou med univ

查看全部 18 位作者收起作者
  • C

    Chen, Likun

    sun yat sen univ

  • W

    Wu, Di

    1 · 2

  • C

    Chen, Xiaobo

    1 · guangzhou med univ

  • Y

    Yang, Yilin

    1 · guangzhou med univ

  • C

    Chen, Tao

    1 · guangzhou med univ

  • X

    Xie, Xiaohong

    1 · guangzhou med univ

  • X

    Xie, Zhanhong

    1 · guangzhou med univ

  • L

    Liu, Ming

    1 · guangzhou med univ

  • O

    Ouyang, Ming

    1 · guangzhou med univ

  • Q

    Qin, Yinyin

    1 · guangzhou med univ

  • L

    Li, Shiyue

    1 · guangzhou med univ

  • Z

    Zhong, Nanshan

    1 · guangzhou med univ

  • G

    Gregg, Jeffrey P.

  • H

    Horita, Nobuyuki

  • S

    Song, Yong (通讯)

    1 · southern med univ

  • Z

    Zhou, Chengzhi (通讯)

    1 · guangzhou med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417